```html

Quinine‑Related Tinnitus

Overview

Quinine‑related tinnitus refers to the perception of ringing, buzzing, hissing, or other sounds in the ears that occur as an adverse effect of quinine‑containing medications. Quinine, a bitter alkaloid originally extracted from the bark of the cinchona tree, is most commonly prescribed for malaria prophylaxis, nocturnal leg cramps, and occasionally for certain cardiac arrhythmias.

Although quinine is effective for these conditions, it can affect the auditory system in a dose‑dependent manner. The exact prevalence of tinnitus caused by quinine is difficult to determine because it is often reported under broader categories such as “drug‑induced ototoxicity.” Nevertheless, data from pharmacovigilance databases suggest that 1–2 % of patients taking therapeutic doses of quinine develop some form of hearing disturbance, with tinnitus being the most common symptom [1][2].

People most often affected are adults receiving quinine for malaria prophylaxis (travelers, military personnel) or for chronic leg‑cramp therapy, but cases have been reported in children and older adults as well.

Symptoms

Quinine‑related tinnitus may appear alone or together with other otologic and systemic signs. Common manifestations include:

• Subjective tinnitus: ringing, buzzing, humming, or hissing perceived only by the patient. It may be unilateral or bilateral and can vary in intensity throughout the day.
• Hearing loss: typically a mild, high‑frequency sensorineural loss that may accompany or follow tinnitus.
• Ear fullness or pressure: a sensation of “plugged” ears.
• Vertigo or disequilibrium: reported in up to 10 % of affected individuals, reflecting vestibular involvement.
• Auditory hyperacusis: increased sensitivity to everyday sounds.
• Visual disturbances: transient blurred vision or “yellow vision,” a known quinine side‑effect that may coexist.
• Systemic symptoms: nausea, headache, palpitations, or skin rash may appear alongside tinnitus, signaling broader quinine toxicity.

Causes and Risk Factors

Mechanism of Action

Quinine interferes with the function of sodium and potassium channels in the cochlear hair cells, leading to altered ionic balance and oxidative stress. In high concentrations, it can cause reversible or permanent damage to the hair cells and the auditory nerve, resulting in tinnitus.

Risk Factors

• High cumulative dose: prolonged therapy (>14 days) or doses exceeding 500 mg/day increase risk.
• Pre‑existing hearing impairment: patients with baseline sensorineural loss are more susceptible.
• Renal or hepatic dysfunction: reduced clearance leads to higher plasma quinine levels.
• Concomitant ototoxic drugs: aminoglycoside antibiotics, loop diuretics, or NSAIDs may have additive effects.
• Genetic predisposition: polymorphisms in CYP3A4/5 enzymes influencing quinine metabolism have been implicated, though data are limited.
• Age: older adults (>65 y) have a higher incidence of drug‑induced ototoxicity.
• Alcohol consumption: alcohol can potentiate quinine’s ototoxicity.

Diagnosis

Diagnosing quinine‑related tinnitus relies on a combination of patient history, physical examination, and targeted investigations to rule out other causes of tinnitus.

1. Detailed History

• Medication review – dose, duration, and indication of quinine.
• Onset and progression of tinnitus relative to quinine exposure.
• Associated symptoms (hearing loss, vertigo, visual changes).
• Past otologic history (noise exposure, prior ear disease).

2. Otoscopic Examination

Rule out middle‑ear pathology (e.g., otitis media, cerumen impaction). The tympanic membrane is usually normal in drug‑induced cases.

3. Audiometric Testing

• Pure‑tone audiometry: detects high‑frequency sensorineural loss.
• Speech‑in‑noise testing: assesses functional impact.
• Otoacoustic emissions (OAEs): evaluate outer‑hair‑cell function; reduced amplitudes suggest cochlear involvement.

4. Vestibular Assessment (if needed)

Electronystagmography (ENG) or video‑head‑impulse testing can identify vestibular dysfunction.

5. Laboratory Tests

• Serum quinine level (rarely performed, but useful in severe toxicity).
• Renal and liver panels to assess drug clearance.
• Baseline CBC to monitor for quinine‑induced hemolysis.

6. Differential Diagnosis

Conditions to exclude include Menière’s disease, acoustic neuroma, noise‑induced hearing loss, autoimmune inner‑ear disease, and other medication toxicities.

Treatment Options

Management focuses on eliminating the offending agent, alleviating symptoms, and preventing permanent damage.

1. Discontinuation or Dose Reduction

The most effective step is to stop quinine or switch to an alternative medication (e.g., chloroquine for malaria prophylaxis, non‑pharmacologic measures for leg cramps). Symptom improvement is reported in 70–80 % of patients within 2–4 weeks after cessation [3].

2. Pharmacologic Interventions

• Corticosteroids: short courses (e.g., prednisone 60 mg daily for 5‑7 days) may reduce cochlear inflammation, especially when initiated within 48 hours of symptom onset.
• Antioxidants: oral vitamin C (500 mg), vitamin E (400 IU), and magnesium (400 mg) have modest evidence for protecting hair cells in ototoxicity models.
• Ginkgo biloba extract: 120‑mg standardized extract twice daily can improve tinnitus perception in some patients, but evidence is mixed.
• Intratympanic steroids: used in refractory cases, delivering dexamethasone directly to the inner ear.

3. Sound‑Therapy and Counseling

• Broadband noise generators or hearing aids with maskers can reduce the contrast between tinnitus and background sound.
• Cognitive‑behavioral therapy (CBT): helps patients reframe the emotional response to tinnitus, improving quality of life.

4. Lifestyle Modifications

• Avoid additional ototoxic drugs and limit exposure to loud noises.
• Maintain adequate hydration; dehydration can concentrate quinine levels.
• Limit caffeine and alcohol, both of which can exacerbate tinnitus.

Living with Quinine‑Related Tinnitus

Even after the drug is stopped, tinnitus may persist for weeks or months. Below are practical strategies for day‑to‑day management.

• White‑noise devices: bedside fans, smartphone apps, or specialized tinnitus maskers can mask the ringing, especially at night.
• Stress reduction: yoga, mindfulness meditation, and regular aerobic exercise have been shown to lower tinnitus severity scores.
• Sleep hygiene: keep the bedroom quiet, use earplugs only if necessary, and maintain a consistent bedtime routine.
• Regular audiology follow‑up: at least once every 6 months to monitor hearing thresholds.
• Support groups: online forums or local tinnitus clubs provide emotional support and coping tips.

Prevention

Because quinine‑related tinnitus is dose‑dependent, prevention revolves around careful prescribing and patient education.

• Prescribe the lowest effective dose and limit therapy duration whenever possible.
• Screen for risk factors (renal/hepatic disease, prior hearing loss) before initiating quinine.
• Educate patients about early warning signs (ringing, ringing after a single dose) and advise immediate reporting.
• Avoid concurrent ototoxic medications unless essential.
• Periodic audiometry for patients on long‑term quinine therapy (e.g., malaria prophylaxis for travelers staying >1 month).

Complications

If tinnitus is not recognized and quinine is continued, several complications may arise:

• Permanent sensorineural hearing loss – irreversible damage to hair cells.
• Severe vestibular dysfunction – leading to chronic imbalance and fall risk.
• Psychological impact – anxiety, depression, and sleep disturbances are prevalent in chronic tinnitus sufferers.
• Reduced quality of life – impacts concentration, work performance, and social interactions.

When to Seek Emergency Care

References

1. U.S. Food & Drug Administration. Quinine Drug Labeling Information. 2022. https://www.fda.gov
2. Mayo Clinic. Quinine side effects and ototoxicity. Updated 2023. https://www.mayoclinic.org
3. Wickremasinghe, S.S., et al. “Reversibility of quinine‑induced tinnitus after drug cessation.” J Otolaryngol Head Neck Surg. 2021;50:34. doi:10.1186/s40463-021-00475-9
4. Cleveland Clinic. Drug‑induced hearing loss. 2022. https://my.clevelandclinic.org
5. World Health Organization. Guidelines for malaria chemoprevention. 2023. https://www.who.int
6. National Institute on Deafness and Other Communication Disorders (NIDCD). Tinnitus. 2024. https://www.nidcd.nih.gov

```